How to position sodium-glucose co-transporter 2 inhibitors in the management of diabetes in acromegaly patients

被引：5

作者：

Zaina, Adnan ^{[1
,2
]}

Prencipe, Nunzia ^{[3
]}

Golden, Elena ^{[1
]}

Berton, Alessandro Maria ^{[3
]}

Arad, Eldad ^{[1
]}

Abid, Ali ^{[1
]}

Shehadeh, Jeryes ^{[4
]}

Kassem, Sameer ^{[5
,6
]}

Ghigo, Ezio ^{[3
]}

机构：

[1] Clalit Med Hlth Care Serv, Div Endocrinol & Metab, Tel Aviv, Israel

[2] Bar Ilan Fac Med, Safed, Israel

[3] Univ Turin, City Hlth & Sci Univ Hosp, Dept Med Sci, Endocrinol Diabet & Metab, Turin, Italy

[4] Clalit Med Hlth Care Serv, Zvulon Med Ctr, Div Cardiol, Tel Aviv, Israel

[5] Carmel Med Ctr, Dept Internal Med, H_efa, Israel

[6] Technion, Fac Med, H_efa, Israel

来源：

ENDOCRINE | 2023年 / 80卷 / 03期

关键词：

ACTING SOMATOSTATIN ANALOGS; GROWTH-HORMONE; CARDIOVASCULAR OUTCOMES; INSULIN-RESISTANCE; RISK-FACTORS; KETOACIDOSIS; DISEASE; PASIREOTIDE; TOLERANCE; MORTALITY;

D O I：

10.1007/s12020-023-03352-4

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：491 / 499

页数：9

共 89 条

[1] Sodium Glucose Co-transporter Inhibitors in Patients with Acromegaly and Diabetes
Adnan, Zaina
[J]. TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2019, 30 (02) : 77 - 79
[2] Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 Inhibitors
Alatrach, Mariam
Laichuthai, Nitchakarn
Martinez, Robert
Agyin, Christina
Ali, Ali Muhammed
Al-Jobori, Hussein
Lavynenko, Olga
Adams, John
Triplitt, Curtis
DeFronzo, Ralph
Cersosimo, Eugenio
Abdul-Ghani, Muhammad
[J]. DIABETES, 2020, 69 (04) : 681 - 688
[3] Amod A, 2020, DIABETES THER, V11, P53, DOI [10.1007/s13300-019-00715-x, 10.2337/dci19-0066]
[4] Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment
Baldelli, Roberto
Battista, Claudia
Leonetti, Frida
Ghiggi, Maria-Rosaria
Ribaudo, Maria-Cristina
Paoloni, Antonella
D'Amico, Eugenio
Ferretti, Elisabetta
Baratta, Roberto
Liuzzi, Antonio
Trischitta, Vincenzo
Tamburrano, Guido
[J]. CLINICAL ENDOCRINOLOGY, 2003, 59 (04) : 492 - 499
[5] Alterations in biomarkers of cardiovascular disease (CVD) in active acromegaly
Boero, L.
Manavela, M.
Gomez Rosso, L.
Insua, C.
Berardi, V.
Fornari, M. C.
Brites, F.
[J]. CLINICAL ENDOCRINOLOGY, 2009, 70 (01) : 88 - 95
[6] Risk factors for development of coronary heart disease in patients with acromegaly: A five-year prospective study
Bogazzi, Fausto
Battolla, Luigi
Spinelli, Cheti
Rossi, Giuseppe
Gavioli, Silvia
Di Bello, Vitantonio
Cosci, Chiara
Sardella, Chiara
Volterrani, Duccio
Talini, Enrica
Pepe, Pasquale
Falaschi, Fabio
Mariani, Giuliano
Martino, Enio
[J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (11) : 4271 - 4277
[7] Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease
Bonnet, F.
Scheen, A. J.
[J]. DIABETES & METABOLISM, 2018, 44 (06) : 457 - 464
[8] Body Composition and Ectopic Lipid Changes With Biochemical Control of Acromegaly
Bredella, Miriam A.
Schorr, Melanie
Dichtel, Laura E.
Gerweck, Anu V.
Young, Brian J.
Woodmansee, Whitney W.
Swearingen, Brooke
Miller, Karen K.
[J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2017, 102 (11) : 4218 - 4225
[9] Diabetes in patients with acromegaly treated with pegvisomant: observations from acrostudy
Brue, Thierry
Lindberg, Anders
van der Lely, Aart Jan
Akerblad, Ann Charlotte
Koltowska-Haeggstrom, Maria
Gomez, Roy
Droste, Michael
Hey-Hadavi, Judith
Strasburger, Christian J.
Camacho-Hubner, Cecilia
[J]. ENDOCRINE, 2019, 63 (03) : 563 - 572
[10] Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
Cefalu, William T.
Leiter, Lawrence A.
Yoon, Kun-Ho
Arias, Pablo
Niskanen, Leo
Xie, John
Balis, Dainius A.
Canovatchel, William
Meininger, Gary
[J]. LANCET, 2013, 382 (9896) : 941 - 950

← 1 2 3 4 5 6 7 8 9 →